SCHEMBL5137495

SCHEMBL5137495

CCCCN(Cc1ccc(OC(F)F)cc1)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 4/20 0.39
ATP4B P51164 4/20 0.39
C5AR1 P21730 1/20 0.39
PDE2A O00408 1/20 0.39
BCHE P06276 3/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
TSHR P16473 2/20 0.38
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
DRD2 P14416 3/20 0.36
DRD3 P35462 3/20 0.36
HSD17B10 Q99714 1/20 0.36
CNR2 P34972 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CRHR1 P34998 1/20 0.36
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913032 0.96 C5AR1 (0.41) C5AR1PDE2ABCHEKDM4EALDH1A1
SCHEMBL650283 0.96 C5AR1 (0.42) ATP4AATP4BC5AR1BCHEKDM4E
SCHEMBL5135971 0.95 C5AR1 (0.41) C5AR1PDE2ABCHEKDM4EALDH1A1
SCHEMBL5136974 0.93 ATP4A (0.39) ATP4AATP4BC5AR1BCHETSHR
SCHEMBL650201 0.93 C5AR1 (0.41) ATP4AATP4BC5AR1BCHEKDM4E
SCHEMBL5135871 0.93 ATP4A (0.44) ATP4AATP4BC5AR1BCHEKDM4E
SCHEMBL5134518 0.92 MAPT (0.39) ATP4AATP4BC5AR1DRD2DRD3
SCHEMBL652364 0.92 C5AR1 (0.41) ATP4AATP4BC5AR1BCHEKDM4E
SCHEMBL648163 0.92 C5AR1 (0.41) ATP4AATP4BC5AR1BCHEKDM4E
SCHEMBL649935 0.92 C5AR1 (0.41) ATP4AATP4BC5AR1BCHEKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed